Yinying Lu

Weihong Ma,1,2,* Yinyin Li,1,* Yinying Lu,1,2 Zhipeng Liang,3 Hongli Yu,1,2 Jie Han,1,2 Jiaqi Liu,1,2 Wenjing Wang,1,2 Caiyun Peng,1 Jiamin Cheng1 1Senior Department of Hepatology, The 5th Medical Center of the PLA General Hospital, Beijing, People’s Republic of China; 2Chinese PLA Medical School, Beijing, People’s Republic of China; 3Guizhou Medical University, Guizhou, People’s Republic of China *These authors contributed equally to this work Correspondence: Jiamin Cheng, Email...

Discussion Our study is the first to describe the presence of NTCP on human liver HSCs obtained from patients with LF. NTCP expression is linearly correlated with fibrosis severity. We also revealed that NTCP mediates BAs uptake in HSCs, triggering their activations. Dysregulation of NTCP through their inhibitions initiated HSC deactivation in an in vitro and in vivo mice model. Targeting NTCP is essential in minimising BAs accumulation in liver and thereby attenuating LF in CCl4-induced mice model.

Sodium+/taurocholate cotransporting polypeptide as target therapy for liver fibrosis Ahmad Salhab1, http://orcid.org/0000-0001-5828-6783Johnny Amer1, Yinying Lu2, Rifaat Safadi1 1Liver Unit, Hadassah-Hebrew University Hospital, Jerusalem, Israel 2Comprehensive Liver Cancer Center, The Fifth Medical Center of PLA General Hospital, Beijing, China Correspondence to Dr Johnny Amer, Liver Unit, Hadassah Medical Center, Jerusalem, Jerusalem, Israel; johnnyamer{at}hotmail.com Abstract Objective...